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Abstract Chronic migraine patients are at risk of devel-
oping a medication overuse. Brain functional studies in
these patients have demonstrated an orbitofrontal hypo-
metabolism, persistent after overuse cessation. Orbito-
frontal dysfunction is also present in addiction and thus
could predispose migraineurs to medication overuse. The
aim of this study was to investigate if orbitofrontal dys-
function can be demonstrated in patients with chronic
migraine and medication overuse by performing a sys-
tematic neuropsychological evaluation focused on tests that
assess frontal lobe function. Second, to establish whether it
is related to the outcome of these patients. We prospec-
tively studied 42 chronic migraine patients with medication
overuse, 42 episodic migraineurs and 41 controls on a
battery of neuropsychological tasks evaluating the orbito-
frontal and dorsolateral functioning. Depression, anxiety,
and personality traits were also assessed. Chronic migrai-
neurs with medication overuse showed a signiﬁcant
impairment in orbitofrontal task performance and higher
depression scores as compared to episodic migraineurs and
controls. Dorsolateral dysfunction was present in both
groups of migraneurs, who also had higher rates of anxiety
as compared to controls. After 1 year of follow-up,
migraine patient’s outcome was classiﬁed according to
their medication overuse status. A negative outcome that
included persistent or new-onset medication overuse was
present in 34% of migraineurs and was associated with
baseline poor orbitofrontal task performance, and with mild
dorsolateral dysfunction, higher rates of depression, anxi-
ety and neuroticism-anxiety traits. Formal education and
years with migraine did not inﬂuence outcome. Orbito-
frontal dysfunction is present in patients with chronic
migraine and medication overuse, and associates with a
poor outcome at 1 year of follow-up. Neuropsychological
evaluation in migraine may help to detect patients prone to
overuse so that appropriate therapeutic attitudes can be
taken.
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Introduction
Medication overuse occurs predominantly in patients with
a primary headache disorder, particularly migraine patients
with a high attack rate [1–4]. Approximately, 10% of
migraine patients develop chronic migraine (CM), a con-
dition characterized by an insidious increase of headache
frequency and intensity that often results in medication
overuse and deterioration of the patient’ quality of life, also
representing a signiﬁcant economic burden [5].
The pathophysiology of this challenging condition is
unclear, but several lines of evidence suggest that neuro-
psychological mechanisms, particularly orbitofrontal (OF)
cortex dysfunction, are involved. A PET study that used
18-FDG in 16 chronic migraineurs with medication over-
use revealed a persistent OF hypofunction before and
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OF hypofunction impairs reward and decision-making
mechanisms [7, 8], occurs in substance abusers, and could
contribute to medication overuse in CM patients. Dorso-
lateral (DL) executive dysfunctions, including planning,
problem solving, and set-shifting tasks have also been
described in patients with migraine [9, 10], although not
clearly related to medication overuse.
Taken together, these ﬁndings suggest that medication
overuse might be a consequence of a susceptibility to
substance abuse due to prefrontal, particularly OF, dys-
function [6].
In this study, we sought to investigate if OF dysfunction
can be demonstrated by performing a systematic neuro-
psychological evaluation focused on tests that assess pre-
frontal lobe functions. We also tried to determine if there is
a relationship between OF functioning and the outcome of
migraine patients in terms of medication overuse.
To this end, we compared a group of chronic migrai-
neurs with medication overuse with episodic migraineurs
and with controls, and followed them for 1 year.
Design and methods
Subjects
Three groups of individuals were included in this study:
(a) Forty-two patients suffering from chronic migraine
and medication overuse (chronic migraine group—
CM group), were consecutively recruited from the
Neurology department at our institution. Inclusion
criteria were age 55 or younger suffering from
chronic migraine and medication overuse according
to the current criteria of the International Headache
Society [3, 11], i.e., deﬁnite or probable migraine
headaches present on[15 days/month for[3 months
and with an intake of simple analgesics on C15 days
per month or of any combination of ergotamine,
triptans, analgesics, and/or opioids on C10 days per
month on a regular basis for [3 months. Exclusion
criteria included a past history of any neurologic
disease different from migraine or a past history of
any psychiatric disorder, except for depression or
anxiety. We also excluded patients with other chronic
pain conditions or under medication for general
medical diseases or taking psychotropic drugs.
(b) Forty-two consecutive patients with episodic
migraine without aura [11] (episodic migraine
group—EM group).The same exclusion criteria as
for the CM group were applied.
(c) Forty-one healthy subjects (control group—CG
group), speciﬁcally without headache disorder or
any other neurological or psychiatric disease, and
under no psychoactive therapy.
All participants had a normal neurologic examination.
All migraineurs had a normal brain MRI or CT scan. Only
six chronic migraine patients and four patients with epi-
sodic migraine had small white matter hyperintensities
consistent with those described in patients with migraine.
After enrolment, they kept a headache calendar to register
the number of days with headache and to keep a medication
record.
Instructions on how to manage a migraine attack with
NSAIDs and triptans were given to all patients, and
appropriate preventive medication was selected or modi-
ﬁed as needed on an individual basis. We avoided using
opioids in these patients. Patients in the CM group were
advised to cease medication overuse and were managed in
an outpatient setting.
Patients (CM and EM) were followed for 1 year with
scheduled visits at 3-month intervals. Special emphasis was
placed in evaluating the status with regards to medication
overuse (i.e., whether overusers converted to a non-ove-
ruser state and vice versa).
At the end of the follow-up, we classiﬁed migraine
patients in two groups in terms of medication overuse:
those with a positive outcome (EM patients that remained
episodic and without medication overuse, and CM over-
using medication that ceased overuse) and those with
a negative outcome (overusers that persisted on this sta-
tus after 1 year of follow-up, and EM patients that started
overusing). We analyzed the differences in the base-
line task performance between both groups and whether
the outcome was related with baseline prefrontal
functioning.
The study was approved by the Ethics Committee of our
Institution and all participants signed a written consent
according to the Helsinki recommendations.
Neuropsychological evaluation
During examination, headache was assessed by a visual
analogue scale ranging from zero (no pain) to ten (worst
headache); patients scoring C4 were asked to perform the
evaluation at some other time. The examination was car-
ried out in two sessions of 1 h duration.
Orbitofrontal assessment
The three following tasks, that have been shown to be
sensitive to ventromedial and OF damage, were employed
[12–17].
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1231. ‘‘Reading the Mind in the Eyes’’ This task consists of
photographs of the eye region of 36 different faces.
The subject is required to make a choice between four
words printed on top and bottom of the picture, and
choose the one that best describes the feeling or
thought of the subject in the photograph.
2. ‘‘Faux-Pas’’ In this test, the subject is read ten stories
that contain a social Faux-Pas and ten stories describ-
ing a minor conﬂict, but in which no Faux-Pas is
committed. The text of each story is placed in front of
the subject so as to reduce the demands on working
memory. The subject should identify the Faux-Pas
stories. If a Faux-Pas is identiﬁed the subject is asked
three questions: ‘‘Why shouldn’t they have said what
they did?’’; ‘‘Why do you think they did it?’’; and
‘‘How do you think the person affected by the Faux-
Pas feel?’’ In every story memory questions (control
questions) are asked to ensure the subject comprehen-
sion (See supplementary material).
3. The ‘‘Empathy Quotient’’ Empathy allows us to
understand the intentions and feelings of others and
predict their behaviour. We employed this self-report
questionnaire for use in adults with normal intelli-
gence. It contains 40 empathy items and 20 ﬁll/control
items. On each empathy item, a score 2, 1 or 0 can be
obtained, so the maximum score of the empathy
quotient is 80.
Dorsolateral assessment
It was evaluated by standard tasks designed to measure
executive function that depends on the dorsolateral frontal
region.
1. Wisconsin card sorting test (WCST) (Heaton 1981,
Psychological Assessment Resources). We employed a
computerized version of this classic task measuring the
ability to display ﬂexibility in the face of changing
schedules of reinforcement.
2. Letters and Numbers (WAIS-III 1997, The Psycho-
logical Corporation): This is a working memory test
measuring the ability to manipulate a progressively
longer piece of information.
3. Trail-making test (TMT) B: The TMT provides
information on visual search, scanning, speed of
processing, mental ﬂexibility, and executive functions
[18].
Personality
Zuckermann–Kuhlman III [19]: Self-administered 99-item
questionnaire measuring impulsive sensation seeking,
neuroticism-anxiety, aggression-hostility, activity, socia-
bility and infrequency (these items detect subjects who
responded carelessly).
Emotional state
Beck depression and anxiety inventories [20]. These
questionnaires consist of 21, self-administered items about
how the subject has been feeling in the last week. Each
question has a set of at least four possible choices ranging
in intensity.
Statistical analysis
Descriptive statistics included frequencies and percentages,
means, standard deviations (SD), and medians and range.
Demographic characteristics and migraine information
were compared between patients with chronic migraine and
medication overuse, patients with episodic migraine and
controls. Neuropsychological tests, and depression, anxiety
and personality tests were also compared between the three
groups. To compare categorical variables Chi-square and
Fisher’s exact tests were used, and for continuous variables
the analysis of variance or the non-parametric Kruskal–
Wallis test was performed. The general lineal model was
used to compare the neuropsychological tests between the
three groups adjusting by age and depression, when nec-
essary. Finally, all the neuropsychological tests were
compared between the patients with positive course of their
clinical status at 1 year of follow-up and those with neg-
ative course. For this comparison, the Student t test or the
Wilcoxon test were performed. Kolmogorov–Smirnov test
was employed to establish the normality of the distribution
of the variables.
Effects were considered signiﬁcant at a p value\0.05.
All statistical analyses were performed using SAS for
Windows statistical software, version 9.1 (SAS Institute,
Inc., Carey, NC, USA).
Results
The main characteristics of the three groups are depicted on
Table 1.
As expected, there was a female predominance in all
groups (v(2)
2 = 5.75, p = 0.0563), and chronic migraine
patients with medication overuse were older than episodic
migraine patients and controls (v(2)
2 = 6.70, p = 0.0350).
There were no signiﬁcant differences in education years
(v(4)
2 = 4.52, p = 0.3397) or in years with headache
(v(2)
2 = 2.14, p = 0.3425) between CM and EM.
CM patients abused from NSAIDs, triptans, simple
analgesics and a variable combination of the above. As
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123mentioned before, we avoid using opioids in these patients,
the reason why these drugs are not represented here.
Different preventive medications were or had been used
in the two groups of migraineurs. Twenty-six EM patients
were not on preventive medication due to the infrequent
headaches, and 11 CM patients refused treatment due to the
lack of consistent efﬁcacy of prior preventive therapies.
Neuropsychological examination (Table 2)
In terms of OF evaluation, the Faux-Pas test revealed sig-
niﬁcant differences, with the CM group performing worse
than the EM group and controls. CM patients detected less
Faux-Pas situations (v(2)
2 = 6.71, p = 0.0349) and detected
a non-existent intentionality to a greater extent than the
other two groups (v(2)
2 = 11.39, p = 0.0034). Other OF
tests did not disclose signiﬁcant differences. The adjusted
models showed that depression was signiﬁcantly associated
with the task Reading the Mind in the Eyes, and in spite of
this adjustment, there were still no signiﬁcant differences
among the three groups.
DL examination found that both groups of migraine
patients performed worse than controls in the Letters and
Numbers test (F(2,121) = 5.62, p = 0.0046). CM patients
had also signiﬁcantly more difﬁculty in reaching the ﬁrst
category on the WCST (v(2)
2 = 9.82, p = 0.0074). The
adjusted models showed that age was signiﬁcantly associ-
ated with all the tasks, and depression only with Letters and
Numbers and categories acquired on the WCST. After the
corresponding adjustments, the results kept equal except
for Trail Making B. We found that CM group performed
signiﬁcantly worse than controls (p = 0.0236).
Emotional and personality measures (Table 3)
Depression scores of CM patients were signiﬁcantly higher
than the other two groups (v(2)
2 = 17.65, p = 0.0001),
whereas both CM and EM showed higher anxiety scores
than controls (v(2)
2 = 10.90, p = 0.0043). No signiﬁcant
differences were found on personality traits.
Follow-up (Table 4)
After 1 year of follow-up, six patients were lost, two in the
CM group and four in the EM group (they refused to attend
the appointments). Twenty-four of the CM patients were
still abusing (60%) and 16 had stopped medication overuse.
In the EM group, three patients had started medication
overuse. Overall, 27 migraine patients (34%) showed a
negative outcome, and 51 had a positive one (see deﬁni-
tions in methods).
We compared the baseline tasks performed by patients
with negative and positive outcome. Patients with a positive
outcome had performed signiﬁcantly better on the three tasks
measuring OF functioning with signiﬁcant differences being
presentinall subtestsofthe Faux-Pas,the ‘‘Readingthemind
in the eye’’ test and the Empathy Quotient.
No differences were found in tasks measuring DL
function, except for one subtest of the WCST, where
patients with a positive outcome performed better than
Table 1 Demographics and migraine information for patients and controls
Chronic migraine with drug overuse Episodic migraine Controls
N (females) 42 (39) 42 (35) 41 (30)
Age, mean (SD), years 41.21 (8.20) 36.19 (8.66) 37.12 (8.59)
Years of education \12 years (17) \12 years (16) \12 years (9)
12–16 years (16) 12–16 years (14) 12–16 years (17)
[16 years (9) [16 years (12) [16 years (15)
Years with migraine \5 years (5) \5 years (9) –
5–15 years (13) 5–15 years (15)
[15 years (24) [15 years (18)
Medication overuse NSAIDs (21), triptans (3), simple analgesics (4),
combination of the above (14)
––
Preventive medication Combination
a (15), amitriptyline (4),
topiramate (4), zonisamide (1), beta-blockers (3),
lamotrigine (1), ﬂunaricine (1),
SSRI (2), no treatment (11)
No treatment (26), beta-blockers (7),
amitriptyline (7), ﬂunaricine (2)
–
Follow-up at 1 year Overuse persisted (24) Continued without overuse (35) –
Ceased overuse (16) Started overuse (3)
Lost to follow-up (2) Lost to follow-up (4)
NSAIDs Non-steroidal anti-inﬂammatory drugs, SSRI selective serotonin reuptake inhibitors
a More than one drug (valproic acid, zonisamide, topiramate, beta-blockers)
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123those with a negative one in reaching the ﬁrst category
(U = 1268, p = 0.0112).
Patients with a negative evolution were signiﬁcantly
more depressed (U = 1207, p = 0.0010) and more anxious
(U = 1143, p = 0.0053) than the positive outcome group.
Regarding personality traits, patients with a negative
course scored signiﬁcantly higher than those with a posi-
tive course in the neuroticism-anxiety factor (t(67) = 2.11,
p = 0.0384).
There were no between-group differences groups in terms
of age, years of migraine or years of formal education.
Discussion
Our results conﬁrm the presence of OF dysfunction in CM
patients with medication overuse from a neuropsycholog-
ical perspective, and suggest that OF dysfunction heralds
a poor prognosis in terms of medication overuse in these
patients. In agreement with some clinical [9] and radio-
logical studies [21], we also found a mild DL dysfunction
in migraineurs (independent of overuse) as compared to
controls. Migraine patients did also show greater anxiety
scores than controls, and overusers were more depressed
than the other two groups. The comorbidity of migraine
with depression has led to suggest a shared pathogenesis
[22].
In keeping with other studies, no differences were found
in personality traits between migraine patients and controls
[23]. We did not observe a relationship between OF dys-
function and the patients’ education level or years of
migraine, which in some studies have been suggested as
risk factors for poor prognosis [24]. Some authors have
proposed that rather than migraine duration it is the fre-
quency and severity of the attacks what determines a
malfunctioning of the circuitries [25] implicated in pain
Table 2 Neuropsychological
tests results
Values expressed as median
(range)
WCST Wisconsin card sorting
test
a Subjects answered the
question: Why do you think
someone did the Faux-Pas? The
patient gives an incorrect
answer when he/she detects
intention in the Faux-Pas (which
was designed as unintentional);
the lower the score, the worse
performance
b Subjects answered the
question: How do you think the
person affected by the Faux-Pas
feels?
Chronic migraine with
drug overuse (n = 42)
Episodic migraine
(n = 42)
Controls
(n = 41)
p
Orbitofrontal tasks
Faux-Pas
Faux-Pas Composite Score 40 (0–59) 47 (0–60) 42 (25–59) 0.0397
Detected Faux-Pas 8 (0–10) 9 (0–10) 8 (5–10) 0.0349
Control questions 40 (38–40) 39.5 (37–40) 40 (37–40) 0.2115
Intentionality
a 6 (0–10) 7 (0–10) 7 (3–10) 0.0034
Empathy
b 7 (0–10) 8 (0–10) 8 (4–10) 0.0825
Reading the Mind in the Eyes 25 (18–31) 26 (14–32) 27 (16–35) 0.2035
Empathy quotient 47 (20–65) 42 (28–59) 47.5 (21–70) 0.2970
Dorsolateral tasks
Trail Making B 74 (37–210) 68 (30–203) 64 (30–119) 0.1306
Letters and Numbers 10 (4–19) 10.5 (4–20) 13 (6–21) 0.0046
WCST
Categories acquired 3 (0–5) 4 (1–5) 4 (0–6) 0.1020
Perseverative errors 7 (2–21) 6 (3–29) 5 (0–22) 0.1116
First category 12 (10–65) 11 (10–33) 12 (10–65) 0.0074
Table 3 Depression, anxiety,
and personality test results
Values expressed as median
(range)
Chronic migraine with
drug overuse (n = 42)
Episodic migraine
(n = 42)
Control
(n = 41)
p
Beck Depression Inventory 13 (0–44) 6 (0–27) 5 (0–22) 0.0001
Beck Anxiety Inventory 12 (1–51) 11 (0–43) 6 (0–35) 0.0043
Zuckerman–Kuhlman personality questionnaire
Impulsive sensation seeking 4 (0–15) 3 (0–11) 2.5 (0–11) 0.4670
Neuroticism–anxiety 8 (1–19) 9 (0–16) 5.5 (1–16) 0.0568
Aggression–hostility 7 (0–14) 7 (2–13) 7 (2–12) 0.6622
Activity 6 (1–16) 7 (1–15) 6.5 (1–14) 0.2660
Sociability 6 (0–9) 6 (0–14) 6 (0–12) 0.1825
Infrequency 1 (0–8) 1 (0–7) 2 (0–6) 0.3770
J Headache Pain (2011) 12:459–466 463
123processing and emotion, that include the OF region. The
baseline frequency of episodic headaches showed a direct
relationship with subsequent risk of chronic daily headache
in another study [26].
The OF cortex is responsible for very complex and
subjective emotional and cognitive functions that are dif-
ﬁcult to evaluate. They include reversal learning [7], social
skills, empathy, and understanding and utilizing social
norms in the appropriate setting, among others [7]. We
have employed a test, the Faux-Pas (see Appendix), that
has been proven quite sensitive to frontal lobe damage,
particularly of the ventromedial and orbitofrontal regions
[16]. A recent meta-analysis also concluded that Faux-Pas
detection is abnormal in the presence of frontal lobe
damage, speciﬁcally of the above mentioned regions [14].
In contrast, evaluating the DL region relies on more con-
ventional tests such as those employed in this study.
The follow-up of these patients was essential to conﬁrm
that OF cortex malfunctioning represented a poor outcome
in terms of medication overuse. In accordance with the
previous data, 7% of our EM patients developed
medication overuse, and 60% of the CM patients persisted
overusing medication [27]; it should be noted, however,
that medication overuse ﬂuctuated throughout the year in
some patients. We observed that those patients with a
negative outcome performed signiﬁcantly worse at baseline
than those with good outcome on the three OF tasks, i.e.,
patients with poor initial OF tests performance had a sig-
niﬁcantly higher risk of medication overuse, even if they
were not abusing at study onset.
Our results and other studies [6] suggest that OF mal-
functioning is present in the CM patients with medication
overuse and predicts a negative outcome. Whether this OF
dysfunction is the cause or is secondary to the abuse is an
unsolved question but we suggest that this dysfunction is
prior to abuse, since those EM patients with the worst
baseline OF tests scores developed medication overuse.
The reason for this dysfunction is unclear. It could be
speculated that as a result of a particular genetic background
and gender (female), environmental factors (low socioeco-
nomic status and education level, obesity), and headache
characteristics (frequency, intensity and duration of pain)
Table 4 Outcome after 1 year
of follow-up
Values expressed as median
(range)
a Patients with chronic
headache that stopped
medication overuse and patients
with episodic headache who
persisted without overuse
b Patients with chronic
headache that persisted
overusing medication and
patients with episodic headache
who converted into chronic
migraine with medication
overuse
Positive outcome
(n = 51)
a
Negative outcome
(n = 27)
b
p
Orbitofrontal tasks
Faux-Pas (FP)
FP Composite Score 46 (0–60) 39 (0–52) 0.0054
Detected FP 9 (0–10) 8 (0–10) 0.0176
Who committed the FP 8 (0–10) 7.5 (0–10) 0.0329
Why is it a FP 8 (0–10) 7 (0–10) 0.0336
Why someone did the FP 6 (0–10) 4 (0–8) 0.0087
Intentionality 7 (0–10) 5 (0–9) 0.0134
Empathy 8 (0–10) 7 (0–10) 0.0150
Reading the Mind in the Eyes 27 (17–32) 23 (14–31) 0.0018
Empathy Quotient 45 (31–65) 44.5 (20–60) 0.0368
Dorsolateral tasks
Trail Making B 68 (30–203) 79.5 (39–210) 0.0803
Letters and Numbers 10 (4–20) 9.5 (4–19) 0.4009
WCST
Categories acquired 4 (0–5) 3 (0–5) 0.0584
Perseverative errors 6 (3–29) 7 (2–20) 0.4625
First category 11 (10–65) 12 (10–65) 0.0112
Beck Depression Inventory 8.5 (0–27) 15.5 (1–44) 0.0010
Beck Anxiety Inventory 10 (0–43) 17.5 (2–51) 0.0053
Zuckerman–Kuhlman personality questionnaire
Impulsive sensation seeking 3 (0–11) 4.5 (0–15) 0.8960
Neuroticism–anxiety 8 (0–16) 11.5 (1–19) 0.0384
Aggression–hostility 6 (0–13) 7.5 (3–14) 0.2075
Activity 7 (1–16) 6 (1–14) 0.8264
Sociability 6 (0–14) 4.5 (0–9) 0.0805
Infrequency 1 (0–8) 1 (0–6) 0.4290
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123there would be a poorly developed prefrontal circuitry that
predisposes these patients to medication overuse. Some
genetic factors for medication overuse have also been
described. Speciﬁcally, a polymorﬁsm in the brain-derived
neurotrophic factor (BDNF) gene (Val66Met) has been
found as a signiﬁcant independent predictor of analgesic
consumption in patients with CM [28]. BDNF is involved in
central pain sensitization and long-term potentiation. Also,
wolframin His611Arg polymorphism inﬂuences medication
overuse headache. Patients with chronic migraine and
medication overuse harbouring that polymorphism showed
a higher monthly medication consumption that non carriers.
Wolframin (WFS1) is involved certain psychiatric illness
and dependence behaviour [29]. Other polymorphisms in
dopamine or serotonine receptors might be involved as
these neurotransmitters control OF thalamo-striatal path-
ways implicated in impulse control. As a result of the pre-
frontal dysfunction, inhibitory response-control functions
are impaired and aberrant enhancements in the limbic-
striatal motivation system appear, so that patients with CM
and medication overuse behave in a similar way as patients
with different addictions, using medication even when it no
longer produces rewarding effect (relief of pain) [30]. In
contrast, DL dysfunction does not seem distinctive of o-
verusers, being present in all types of migraineurs. Only the
ability to arrange by categories, a subtest of the WCST,
distinguished negative outcome patients, but this task can
also be altered with OF dysfunction [31]. However, normal
DL functioning is important in painful conditions, since this
region exerts active control on pain perception by modu-
lating corticosubcortical and corticocortical pathways [32].
The role of DL cortex in medication overuse cannot be
inferred from our results.
In our study, other factors associated to poor prognosis
were the levels of depression, anxiety, and neuroticism
traits. Some authors have reported that individual differ-
ences in fear and anxiety modulate the pain response and
may even cause more suffering [33]. This modulation is
exerted by prefrontal mesial and orbitofrontal systems.
Impulsivity trait represents a comorbidity that contributes
to substance abuse although this speciﬁc trait was not
overrepresented in our CM group.
This study has some limitations. First, patients with CM
were older than EM patients, as reported in epidemiolog-
ical studies, and age could represent a confounding factor.
We performed a lineal model adjusting by age, and found
no differences in our results at one-year follow-up. Second,
preventive medication varied among the patients in the CM
group. While 11 patients with chronic migraine were not
taking any preventive medication because all drugs had
failed, other patients were taking two or more (Table 1).
We do not believe, however, that preventive medication
played a role in their performance on the
neuropsychological evaluation. Third, the levels of anxiety
and depression were assessed using a self-administered
psychometric tool, the Beck anxiety and depression
inventory. A complete psychiatric assessment could have
detected more precisely the emotional state of the patients,
but was out of the scope of this study.
Basedonourresults,weconcludethatOFdysfunctioncan
be detected in CM patients with medication overuse with
appropriate neuropsychological tests. The impairment in OF
tasks predicts a poor prognosis regarding headache outcome
and medication overuse in these patients. They would beneﬁt
of a neuropsychological examination with emphasis on
detectingOFdysfunction,anxietyanddepressionsothatthey
could beneﬁt of an early and aggressive multidisciplinary
therapeutic intervention, such as psychological and psychi-
atric attention, monthly neurological interviews for treatment
follow-up or hospital admissions for analgesic cessation.
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